期刊文献+

细针吸取结合液基细胞学对甲状腺乳头状癌的免疫组化分析 被引量:2

The Immunocytochemistry Analysis of Papillary Thyroid Cancer in FNA′s Using Liquid-Based Cytology
下载PDF
导出
摘要 目的应用甲状腺细针吸取细胞学进行取样,通过液基细胞学方法对标本进行处理,结合免疫组化方法,探讨对甲状腺乳头状癌诊断有价值的诊断指标。方法对85名甲状腺乳头状癌患者进行FNA取样后,应用液基薄层细胞学方法,分析一组免疫标记物CK-19、Galectin-3、HBME1、CD-44v、CD-56和E-Cad-herin与甲状腺乳头状癌的关系。结果 CK-19、Galectin-3、HBME1、CD-44v表达阳性分别为78例(91.8%)、74例(87.1%)、64例(75.3%)和73例(85.9%),CD-56和E-cadherin的失表达分别为81例(95.3%)和80例(94.1%)。结论液基细胞学检查能提高甲状腺乳头状癌诊断的准确性;CK-19、Galectin-3、HBME-1和CD-44v的阳性表达对甲状腺乳头状癌有诊断意义,为诊断甲状腺乳头状癌提供了一种可靠而有前景的诊断方法。 [ Objective ] To explore the diagnostic value of papillary carcinoma indicators by the methods of thyroid fine-needle aspiration cytology, liquid-based cytology, and immunohistoehemical methods. [ Methods ] A number of 85 fine needle aspirations, positive for papillary thyroid cancer were studied using Thin Layer Cytology. A panel of the immune markers CK-19, Galectin-3, HBME1, CD-44v, CD-56, and E-eadhefin was performed. [Resuits] Positive expression of CK-19 was observed in 78 (91.8%), of Galeetin-3 in 74 cases (87.1%), HBME1 in 64 cases (75.3%), and of CD-44v in 73 cases (85.9%). Loss of expression of CD-56 was observed in 81 cases (95.3%) and of E-cadherin in 80 cases (94.1%). [ Conclusions ] The diagnostic accuracy of thyroid papillary carcinoma can be improved by liquid based cytology can improve. CK-19, Galectin-3, HBME-1 and CD-44v positive expression were significant for the diagnosis of papillary thyroid cancer, moreover they provides a reliable and promising diagnostic method for it.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第27期3380-3382,3386,共4页 China Journal of Modern Medicine
关键词 甲状腺乳头状癌 细针吸取细胞学 液基薄层细胞学 免疫标记物 PTC FNA Liquid-Based Cytology immune markers
  • 相关文献

参考文献15

  • 1H-M. KO, I-K JHU, S-H YANG, et al. Clinicopathologic analy- sis of fine needle aspiration cytology of the thyroid: a review of 1 613 cases and correlation with histopathologic diagnoses[J]. Acta Cytologica, 2003, 47(5): 727-732.
  • 2ED ROSSI, M RAFAELI, C MINIMO, et al. Immunohistochemi- cal evaluation of thyroid neoplasms in Thin-Layer smears from fine needle aspiration biopsie[j]. Cancer Cytopathology, 2005, 105(2): 87-95.
  • 3黄悦,赵建华,樊克武.HBME-1和CK19、Galectin-3在甲状腺乳头状癌中表达及诊断价值[J].南京医科大学学报(自然科学版),2007,27(11):1294-1297. 被引量:13
  • 4欧阳电,陈福进,魏茂文,杨安奎,陈振清,李秋梨,陈艳峰.Galectin-3在分化型甲状腺癌细胞中的表达及其临床意义[J].癌症,2005,24(11):1367-1371. 被引量:4
  • 5DEI DEMELLAWY, AL NASR, S BABAY, et al. Diagnostic u- tility of CD56 immunohistochemistry in papillary carcinoma of the thyroid [J]. Pathology Research and Practice, 2009, 205 (5): 303-309.
  • 6ML PRASAD, N S PELLEGATA, Y HUANG, et al. fibronectin-1, CITED-1, HBME1 and cytokeratin-19 tochemistry is useful for the differential diagnosis of mors[J]. Modern Pathalogy, 2005, 18(1): 48-57.
  • 7K KAWACHI, Y MATSUSHITA S, YONEZAWA, et al. Galectin-3 expression in various thyroid neoplasms and its possi- ble role in metastasis formation[J]. Human Pathology, 2000, 31(4): 428 - 433.
  • 8H INOHARA, Y HONJO, T YOSHII, et al. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker dif- ferentiating benign from malignant thyroid neoplasms [J]. Cancer, 1999, 85(11): 2475-2484.
  • 9DL SEGEV, D P CLARK, M A ZEIGER, et al. Beyond the suspicious thyroid fine needle aspirate: a review[J]. Acta Cytalog- ica, 2003, 47(5): 709-722.
  • 10A BARTOLAZZI, F ORLANDI, E SAGGIORATO, et al. Galectin-3-expression analysis in the surgical selection of fol- licular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multieentre study[J]. The Lancet Ontolo- gy, 2008, 9(6): 543-549.

二级参考文献26

  • 1陈福进,李秋梨,曾宗渊,宋明,杨安奎,张诠.分化型甲状腺癌的治疗及影响复发的因素分析[J].癌症,2004,23(11):1311-1316. 被引量:50
  • 2方海飞,沈美萍,徐银峰.甲状腺乳头状癌TGF-β_1、CD_(31)表达与肿瘤转移的关系[J].南京医科大学学报(自然科学版),2007,27(5):472-475. 被引量:16
  • 3Gasbarri A, Martegani MP, Del Prete F, et al. Galectin-3and CD44v6 isoforms in the preoperative evaluation of thyroid nodules [J]. J Clin Oncol, 1999,17(11): 3494-3502.
  • 4Cvejic D, Savin S, Paunovic I, et al. Immunohistochemical location of galectin-3 in malignant and benign human thyroid tissue [J]. Anticancer Res, 1998,18(4A) :2637-2641.
  • 5Xu XC, el-Naggar AK, Lotan R, et al. Differental expression of galectin-1 and galectin-3 in thyroid tumors [J]. Am J Pathol, 1995,147 (3): 815-822.
  • 6Barry W, David H, George M, et al. The M.D. Anderson surgical oncology handbook [M]. 2nd ed. Lippincott Williams Wilkins, 1999:98.
  • 7Orlandi F, Saggiorao E, Pivano G, et al. Galectin-3 is a presurgical marker of thyroid carcinoma [J]. Cancer Res,1998,58(14) :3015-3020.
  • 8Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid disease [J]. Lancet, 2001,357 (9269):1644-1650.
  • 9Iurisci I, Tinari N, Natoli C, et al. Concentrations of Galectin-3 in the sera of normal controls and cancer patients [J]. Clin Cancer Res, 2000,6(4): 1389-1393.
  • 10汪玉松 邹思湘 张玉静.动物生物化学[M](第2版)[M].北京:中国农业科技出版社,2002.94-96.

共引文献15

同被引文献18

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部